Optimal Clinical Predictors to AKI in Cirrhotic Patients Experienced Acute Gastrointestinal Hemorrhage

2019-12-09 00:56:22 | BioPortfolio


Acute kidney injury (AKI) is a common complication, occurring in approximately 20% of hospitalized cirrhotic patients and has a significant negative impact on patients' outcomes according to either the initial stage (at the time of the first fulfillment of AKI criteria), or the peak stage (at the peak value of serum creatinine concentration during hospitalization). Among all the precipitating factors to cirrhotic AKI, acute gastrointestinal hemorrhage is a common cause that leads to a decrease in effective arterial blood volume in the hyperdynamic circulatory status of cirrhosis. However, there is still lack of optimal predictors to developing AKI in cirrhotic patients suffering from acute GI bleeding. A number of biomarkers associated with AKI were recently described. Some studies have shown that these novel biomarkers increase with the severity of liver injury and are predictive of clinical outcomes. However, the effective prediction, definitive diagnosis and differentiation of AKI by these biomarkers are still controversial. Furthermore, there is no clinical studies focus on the applicability and potential alteration in the setting of acute gastrointestinal hemorrhage in patients with cirrhosis. Aim and significance: In this study, we aim to investigate the capability of novel renal biomarkers in predicting development of acute kidney injury, differentiating causes (between pre-renal AKI, acute tubular necrosis, and hepatorenal syndrome), and predicting the response to renal treatment as well as the hepatic and overall outcomes in patients with cirrhosis suffering from acute gastrointestinal hemorrhage.


Specific aims of this study :

1. To examine the influences of acute gastrointestinal hemorrhage on the serological or urinary level of novel renal biomarkers in patients with cirrhosis.

2. To investigate the ability of novel biomarkers to predict the development of acute kidney injury and the response to renal salvage treatment in patients with cirrhosis suffering from acute gastrointestinal hemorrhage.

3. To investigate the ability of novel biomarkers to differentiate the precipitating factors (such as sepsis-induced AKI, hypervolemia-induced AKI, etc.) and the causes of AKI between pre-renal AKI, acute tubular necrosis, and hepatorenal syndrome.

4. To investigate the ability of these novel biomarkers to predict the hepatic and overall outcomes in patients with cirrhosis suffering from acute gastrointestinal hemorrhage.

Estimation of sample size :

According to previous studies, the estimated incidence of AKI in cirrhotic patients suffering from gastrointestinal hemorrhage is about 10-15%. The type 1 error is set as 0.05; and the type 2 error is set as 0.2. Then, the calculated sample size is about 80. Considering the possibility of loss of follow-up is about 10%, the estimated sample size will be about 90 patients.

Sample collection and laboratory experiments:

Patients will be prospectively followed from admission until discharge.

1. Sample collection: A fresh 30-mL of urine sample will be collected either by way of clean catch or Foley catheter tubing will be collected at the time in admission to our hospital, at the peak stage of AKI, and after the recovery (if recovery occurs) 10cc of blood will be collected from the peripheral vessel once at the time in admission to our hospital, at the peak stage of AKI, and after the recovery (if recovery occurs).

2. Abdominal sonography (including evaluation of bilateral kidneys) will be arranged if no image study available within 3 months upon admission.

Urine examination:

urinary neutrophil gelatinase-associated lipocalin (NGAL), IL-18, spot urine protein, albumin, creatinine, urea nitrogen, sodium, kidney injury molecule 1 (KIM-1), liver-type fatty acid binding protein (L-FABP), insulin-like growth factor, and tissue inhibitor metalloproteinase will be measured.

Serum examination:

serum NGAL, cystatin C, blood urea nitrogen, creatinine, uric acid, IL-1, tumor necrosis factor alfa will be measured.

Record clinical information and regular follow-up:

Record any precipitating factors, including: presence of active infection or sepsis, the dosage and types of diuretics, presence of acute hemorrhage, the frequency and the drainage volume of each therapeutic paracentesis, supplement of albumin or other colloid fluid, presence of heart failure or active pulmonary problems, prescription of non-selective beta blockers, non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics, herbs and other nephrotoxic drugs, as well as others. Record any chronic underlying diseases, including: diabetes mellitus, hypertension, congestive heart failure (the baseline left ventricular ejection rate if available), chronic kidney disease (baseline glomerular filtration rate), autoimmune disease, anemia of chronic disorder, the severity of liver diseases (such as status of ascites, serum albumin level, presence of varices, etc.), and so on.

Regular follow-up of renal function and fluid status at least twice per week as the routine management in clinical practice. Regular measurements of patients' clinical data, including vital signs will be done in daily practice.

Detailed laboratory methods:

Urine samples will be immediately refrigerated and then centrifuged at 5,000g for 10 minutes at −4°C. Aliquots of 1 mL of supernatant will be subsequently stored within 6 hours of collection in cryovials at −80°C for NGAL, IL-18, KIM-1, L-FABP, albumin, sodium, and creatinine measurements. No additives or protease inhibitors will be used. All biomarkers will be measured from frozen aliquots that will not undergo any additional freeze-thaw cycles. Laboratory measurements will be performed by personnel blinded to patient information.

Study Design


Gastrointestinal Hemorrhage


Taipei Veterans General Hospital, Taiwan


Enrolling by invitation


Taipei Veterans General Hospital, Taiwan

Results (where available)

View Results


Published on BioPortfolio: 2019-12-09T00:56:22-0500

Clinical Trials [889 Associated Clinical Trials listed on BioPortfolio]

Glasgow-Blatschford Score Validation in Digestive Hemorrhage

The purpose of this study is to validate the Glasgow-Blatchford score for the stratification of patients with upper gastro-intestinal hemorrhage. This score is easy to calculate. It is mai...

Hemospray in Gastrointestinal Bleeding: A Real-life Multicenter Cohort

This is an observational, retrospective, analytical, and multicenter study conducted at 17 hospitals. Our research aims to assess the effectiveness of Hemospray® in patients with gastroin...

Pharmacogenetics of Gastrointestinal Bleeding

Gastrointestinal bleeding is a severe adverse effect occurring in subjects secondary to the use of nonsteroidal anti-inflammatory drugs (NSAIDs). The enzyme CYP2C9 is responsible for the e...

Study of the Risk Factors and Outcomes After Gastrointestinal Bleeding

The purpose of this multicenter, two component observational and standardized case-control study is to evaluate risk factors of gastrointestinal (GI) bleeding with a prospective 3-month an...

Clinical Investigation of Safety and Performance of a Medical Device (ClearPlasma) for the Treatment of Patients With Acute Upper Gastrointestinal Hemorrhage.

Pre-market, multi-center, international, double-blind, randomized, controlled, prospective, first-in-human clinical investigation of a Class IIb Investigational Medical Device, in which Pa...

PubMed Articles [2501 Associated PubMed Articles listed on BioPortfolio]

Nationwide Analysis of Resource Utilization and In-Hospital Outcomes in the Obese Patients With Lower Gastrointestinal Hemorrhage.

The goal of this study was to evaluate the impact of obesity on the outcomes of patients with lower gastrointestinal hemorrhage (LGIH).

Intravenous Access in Gastrointestinal Hemorrhage: A Multidisciplinary Quality Improvement Initiative Led by Emergency Department Nurses and Internal Medicine Physicians.

The management of acute gastrointestinal hemorrhage (GIH) is focused on early resuscitation through 2 large-bore intravenous (2LBIV) catheters, although adherence to this recommendation is low.

Evaluation of the guaiac fecal occult blood test for detection of gastrointestinal bleeding in the rhesus macaque (Macaca mulatta).

Gastrointestinal (GI) hemorrhage accompanies several common diseases of rhesus macaques (Macaca mulatta). Guaiac fecal occult blood testing (gFOBT) is a non-invasive means to detect such bleeding in s...

Varices: Esophageal, Gastric, and Rectal.

Gastrointestinal varices are associated with cirrhosis and portal hypertension. Variceal hemorrhage is a substantial cause of morbidity and mortality, with esophageal and gastric varices the most comm...

An unusual cause of massive GI hemorrhage in an adult.

Medical and Biotech [MESH] Definitions

Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.

Acquired degenerative dilation or expansion (ectasia) of normal BLOOD VESSELS, often associated with aging. They are isolated, tortuous, thin-walled vessels and sources of bleeding. They occur most often in mucosal capillaries of the GASTROINTESTINAL TRACT leading to GASTROINTESTINAL HEMORRHAGE and ANEMIA.

Bleeding from a PEPTIC ULCER that can be located in any segment of the GASTROINTESTINAL TRACT.

Hemorrhage within the orbital cavity, posterior to the eyeball.

Intraocular hemorrhage from the vessels of various tissues of the eye.

More From BioPortfolio on "Optimal Clinical Predictors to AKI in Cirrhotic Patients Experienced Acute Gastrointestinal Hemorrhage"

Quick Search

Relevant Topic

Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Searches Linking to this Trial